131I-tositumomab (Bexxar®) vs.90Y-ibritumomab (Zevalin®) therapy of low-grade refractory/relapsed non-hodgkin lymphoma

Molecular Imaging and Biology

Volumn 12, Issue 2, 2010, Pages 198-203

  Iagaru, Andrei ^a   Mittra, Erik S ^a   Ganjoo, Kristen ^b   Knox, Susan J ^a   Goris, Michael L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bexxar; Lymphoma; Non Hodgkin; Therapy; Zevalin

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; PREDNISOLONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER GRADING; CANCER RELAPSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; SAMPLE SIZE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; MIDDLE AGED; RECURRENT DISEASE; SCINTISCANNING; WHOLE BODY IMAGING;

MURINAE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 77953538545     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0245-9     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics. CA Cancer J Clin 58(2):71-96
2. Young GA, Iland HJ (2007) Clinical perspectives in lymphoma. Intern Med J 37(7):478-484
3. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM et al (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 23 (30):7565-7573
4. Wiseman GA, Conti PS, Vo K, Schilder RJ, Gordon LI, Emmanouilides C et al (2007) Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma 7(8):514-517 (Pubitemid 350054864)
5. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M et al (1996) 90-Y-labeled anti-CD20 monoclonal antibody therapy of recurrent B cell lymphoma. Clin Cancer Res 2(3):457-470
6. Knox SJ, Goris ML, Wessels BW (1992) Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol 23(2):111-117
7. Knox SJ, Levy R, Miller RA, Uhland W, Schiele J, Ruehl W et al (1990) Determinants of the anti-tumor effect of radiolabelled monoclonal antibodies. Cancer Res 50(16):4935-4940
8. Knox SJ, Sutherland W, Goris ML (1993) Correlation of tumor sensitivity to low dose rate irradiation with G2/M-phase block and other radiobiological parameters. Radiat Res 135(1):24-31
9. Langmuir VK, Fowler JF, Knox SJ, Wessels BW, Sutherland RM, Wong JY (1993) Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med Phys 20(2 Pt 2):601-610
10. Zinzani PL, d'Amore F, Bombardieri E, Brammer C, Codina JG, Illidge T et al (2008) Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Eur J Cancer 44(3):366-373
11. Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J et al (1995) Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13(1):140-147
12. Horning SJ, Younes A, Kroll S, Jain V, Lucas J, Podoloff D et al (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma progressive after rituximab. J Clin Oncol 23(4):712-719
13. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L et al (2001) Pivotal study of I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19(19):3918-3928
14. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352(5):441-449
15. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A et al (2004) The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10(23):7792-7798
16. Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J et al (2004) Phase I trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Blood 104 (1):227-236
17. Jacene HA, Filice R, Kasecamp W, Wahl RL (2007) Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med 48(11):1767-1776